Sucralfate oral suspension (sucralfate) NDC 68462-827

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-827Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0827Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-827-61	68462082761	420 mL in 1 BOTTLE (68462-827-61)Marketed from Jan 5, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate oral suspension
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212141
Marketing start: Jan 5, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 68462-827_1e595c2a-edd0-43f7-a2db-69553b9557d9SPL ID 1e595c2a-edd0-43f7-a2db-69553b9557d9SPL set ID 1e595c2a-edd0-43f7-a2db-69553b9557d9RxCUI 313123UNII XX73205DH5UPC 0368462827611
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462082761 followed by a unit qualifier and the quantity

Package 68462-0827-61. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 6, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)